Clinical Trial Detail

NCT ID NCT04351230
Title Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Academic and Community Cancer Research United
Indications

Her2-receptor positive breast cancer

Therapies

Abemaciclib + Ado-trastuzumab emtansine

Ado-trastuzumab emtansine

Age Groups: adult senior

Additional content available in CKB BOOST